NASDAQ:VRAYViewray Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Viewray Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.45 +0.08 (+3.38 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$2.34Now: $2.45▼$2.5350-Day Range$1.35MA: $2.49▼$3.3752-Week Range$1.11Now: $2.45▼$9.76Volume1.70 million shsAverage Volume2.40 million shsMarket Capitalization$361.23 millionP/E RatioN/ADividend YieldN/ABeta1.18 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingViewray has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 7 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.61, Viewray has a potential upside of 129.0% from its current price of $2.45.Amount of Analyst CoverageViewray has only been the subject of 4 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesViewray has received 269 “outperform” votes. (Add your “outperform” vote.)Underperform VotesViewray has received 211 “underperform” votes. (Add your “underperform” vote.)Community SentimentViewray has received 56.04% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Viewray and other stocks. Vote “Outperform” if you believe VRAY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VRAY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldViewray does not currently pay a dividend.Dividend GrowthViewray does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Viewray insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 15.48% of the stock of Viewray is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Viewray are expected to decrease by -8.75% in the coming year, from ($0.80) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viewray is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viewray is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViewray has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.22 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VRAY Previous Symbol CUSIPN/A CIK1597313 Webhttp://www.viewray.com/ Phone440-703-3210Debt Debt-to-Equity Ratio0.25 Current Ratio5.28 Quick Ratio4.35Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$87.78 million Price / Sales4.12 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book1.67Profitability EPS (Most Recent Fiscal Year)($1.18) Net Income$-120,200,000.00 Net Margins-136.93% Return on Equity-81.70% Return on Assets-41.98%Miscellaneous EmployeesN/A Outstanding Shares147,440,000Market Cap$361.23 million Next Earnings Date5/7/2020 (Estimated) OptionableOptionable Receive VRAY News and Ratings via Email Sign-up to receive the latest news and ratings for VRAY and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:VRAY Rates by TradingView Viewray (NASDAQ:VRAY) Frequently Asked Questions How has Viewray's stock been impacted by COVID-19 (Coronavirus)? Viewray's stock was trading at $1.69 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VRAY shares have increased by 45.0% and is now trading at $2.45. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Viewray? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Viewray. When is Viewray's next earnings date? Viewray is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Viewray. How were Viewray's earnings last quarter? Viewray Inc (NASDAQ:VRAY) issued its quarterly earnings results on Thursday, March, 12th. The company reported ($0.31) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.06. The business had revenue of $16.47 million for the quarter, compared to the consensus estimate of $17.05 million. Viewray had a negative return on equity of 81.70% and a negative net margin of 136.93%. View Viewray's earnings history. What guidance has Viewray issued on next quarter's earnings? Viewray updated its FY 2020 After-Hours earnings guidance on Thursday, March, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $58-95 million, compared to the consensus revenue estimate of $110.15 million. What price target have analysts set for VRAY? 10 analysts have issued 12 month price objectives for Viewray's stock. Their forecasts range from $2.00 to $8.00. On average, they anticipate Viewray's share price to reach $5.61 in the next year. This suggests a possible upside of 129.0% from the stock's current price. View analysts' price targets for Viewray. Has Viewray been receiving favorable news coverage? Headlines about VRAY stock have been trending very negative recently, InfoTrie reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Viewray earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutViewray. Who are some of Viewray's key competitors? Some companies that are related to Viewray include Natus Medical (NTUS), InMode (INMD), Zynex (ZYXI), AxoGen (AXGN), TransMedics Group (TMDX), Semler Scientific (SMLR), Stereotaxis (STXS), BioLife Solutions (BLFS), Cutera (CUTR), Rockwell Medical (RMTI), Soleno Therapeutics (SLNO), Fonar (FONR), BioSig Technologies (BSGM), Edap Tms (EDAP) and Fc Global Realty (FCRE). What other stocks do shareholders of Viewray own? Based on aggregate information from My MarketBeat watchlists, some companies that other Viewray investors own include Amarin (AMRN), Alibaba Group (BABA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Pieris Pharmaceuticals (PIRS), Zynerba Pharmaceuticals (ZYNE), Anavex Life Sciences (AVXL) and Cara Therapeutics (CARA). When did Viewray IPO? (VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers. What is Viewray's stock symbol? Viewray trades on the NASDAQ under the ticker symbol "VRAY." How do I buy shares of Viewray? Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Viewray's stock price today? One share of VRAY stock can currently be purchased for approximately $2.45. How big of a company is Viewray? Viewray has a market capitalization of $361.23 million and generates $87.78 million in revenue each year. The company earns $-120,200,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. View additional information about Viewray. What is Viewray's official website? The official website for Viewray is http://www.viewray.com/. How can I contact Viewray? Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected] This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: How do taxes affect a CDs total return?
